Primary Immunodeficiency Disease News

The FDA has approved 50 ml/10 gm prefilled syringes of Hizentra for treating patients with primary immunodeficiency aged 2 years and older and adults with chronic inflammatory demyelinating polyneuropathy, according to a press release.

The FDA has approved a supplemental biologics license application for the use of Hyqvia to treat primary immunodeficiency in children aged 2 to 16 years, according to a press release from Takeda.

The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.

SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Children born to mothers, not fathers, with primary antibody immunodeficiencies had greater risks for certain psychiatric disorders and for suicidal behavior, according to data published in JAMA Psychiatry.

Long-term joint exposure to multiple air pollutants at low concentrations may be associated with an increased risk of depression and anxiety, according to a study published in JAMA Psychiatry.

LOUISVILLE, Ky. — Patients with primary immunodeficiency disease experienced fewer infections during the COVID-19 lockdown, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Nearly 3 years into the pandemic, COVID-19 continues to dominate headlines and research labs as scientists explore therapies that mitigate the impact of the virus, particularly among patients with asthma and allergy.

Infants with Artemis-deficient severe combined immunodeficiency improved after corrected genes in their stem cells enabled them to grow their own T cells and B cells, according to a study published in The New England Journal of Medicine.

A two-step analytical pipeline facilitated the identification of individuals with primary immunodeficiency and accurately quantified their clinical risk, according to a study published in The Journal of Allergy & Clinical Immunology.